Memory Disorders Clinical Trials

Featured Study

The Digital Biomarkers study is testing whether study participants can be assessed for their ability to learn, understand, and remember along with their activities of daily living using novel smartphone technology. It will also study whether there is any relation between commonly used tests to assess thinking abilities and memory and sensor data collected on smartphones. This is a multicenter, pilot study looking to recruit approximately 5 participants with early AD and 5 healthy participants who do not report a formal decline in their thinking abilities. To be eligible for Digital Biomarkers, a person must be 65 years or older, have experience with smartphone or tablet technology, have adequate visual and auditory acuity, and be willing to complete all aspects of the study, including an MRI and PET brain scan. The total duration of participation is 30 days with the addition of a screening period of up to 6 weeks. To learn more about this research study opportunity enrolling at the Stanford Neuroscience Health Center, contact the Study Coordinator, Viktoriya Bourakova, at (650) 709-9041 or viktoriya.bourakova@stanford.edu.

Stanford Memory Disorders Clinical Trials

Active, recruiting:

Sponsor: Digital Biomarker
Intervention
: None/Observational
Indication
:  Healthy Controls/MCI/Mild AD
PI
: Sharon Sha, MD
Contact:
 Viktoriya Bourakova, viktoriya.bourakova@stanford.edu

Sponsor: Eisai/NIH (AHEAD3-45)
Intervention
: BAN2401 (monoclonal antibody binding to amyloid)
Indication
: Cognitively Unimpaired
Clinicaltrials.gov identifier:
NCT04468659
PI
: Sharon Sha, MD
Contact:
 Anthony Velasquez, anthgv@stanford.edu, and Amanda Ng, amandang@stanford.edu

Sponsor: Alzheimer's Disease Cooperative Study (PeaceAD Study)
Intervention
: Prazosin
Indication
: Probable or possible AD and disruptive agitation
Clinicaltrials.gov identifier: 
NCT03710642
PI
: Victor Henderson, MD and Sharon Sha, MD
Contact:
 Amanda Ng, amandang@stanford.edu

Active, not recruiting:

Sponsor: Eisai (Clarity AD)
Intervention
: BAN2401 (monoclonal antibody binding to amyloid)
Indication
: MCI/Mild AD
Clinicaltrials.gov identifier: 
NCT03887455
PI
: Sharon Sha, MD
Contact:
 Viktoriya Bourakova, viktoriya.bourakova@stanford.edu

Sponsor: Biogen (Tango Study)
Intervention
: BIIB092 (Monoclonal antibody binding to tau)
Indication
: MCI/Mild AD
Clinicaltrials.gov identifier: 
NCT03352557
PI
: Sharon Sha, MD
Contact:
 Viktoriya Bourakova, viktoriya.bourakova@stanford.edu

Sponsor: Cortexyme (Gain Study) 
Intervention
: COR388 (Gingipain inhibitor) 
Indication
: Mild to Moderate AD
Clinicaltrials.gov identifier: 
NCT03823404
PI
: Sharon Sha, MD
Contact:
 Amanda Ng, amandang@stanford.edu

Sponsor: Biogen (Embark Study)
Intervention
: Aducanumab (Monoclonal antibody binding to amyloid)
Indication
: MCI/Mild AD (Recruiting by invitation only: participants who were previously enrolled in aducanumab trials) 
Clinicaltrials.gov identifier: 
NCT04241068
PI
: Sharon Sha, MD
Contact:
 Anthony Velasquez, anthgv@stanford.edu

Completing, not recruiting:

Sponsor: Genentech (Tauriel Study)
Intervention
: RO7105705 (Monoclonal antibody binding to tau)
Indication
: MCI/Mild AD
Clinicaltrials.gov identifier: 
NCT03289143
PI
: Sharon Sha, MD
Contact:
 Jenn Gaudioso, jenn.gaudioso@stanford.edu

Sponsor: Genentech (Lauriet Study)
Intervention
: RO7105705 (Monoclonal antibody binding to tau)
Indication
: Moderate AD
Clinicaltrials.gov identifier: 
NCT03828747
PI
: Sharon Sha, MD
Contact: 
Jenn Gaudioso, jenn.gaudioso@stanford.edu

Sponsor: Novartis (Generations II Study)
Intervention:
 CNP520 (Active BACE-1 Inhibitor)
Target Population:
 Cognitively Unimpaired APOEHomozygotes or Amyloid Positive Heterozygotes
Clinicaltrials.gov identifier: 
NCT03131453
PI
: Sharon Sha, MD
Contact:
 Amanda Ng, amandang@stanford.edu

Sponsor: Novartis (Generations I Study)
Intervention:
 CAD106 (Induces Active Antibody without activating Aβ-reactive T cells) and CNP520 (BACE-1 Inhibitor)
Target Population:
 Cognitively Unimpaired APOEHomozygotes
Clinicaltrials.gov identifier: 
NCT02565511
PI
: Sharon Sha, MD
Contact:
 Amanda Ng, amandang@stanford.edu

Clinical trials contacts

memoryresearch@stanford.edu
(650) 724-8736

Sharon Sha, MD, MS
Clinical Assistant Professor, Neurology & Neurological Sciences
Director, Memory Disorders Clinical Trials
ssha1@stanford.edu
(650) 723-5072